The rapid proliferation of telehealth platforms offering weight-loss medications has outpaced regulatory oversight, creating a landscape where patients may receive powerful metabolic drugs with minimal clinical scrutiny. Understanding how rigorously — or not — these digital prescribers assess patient safety before dispensing GLP-1 receptor agonists has direct implications for millions of adults seeking treatment outside traditional care settings.
This secret shopper investigation, published in JAMA, systematically probed the prescribing practices of online vendors offering GLP-1 receptor agonists such as semaglutide and tirzepatide. Trained investigators posed as prospective patients and documented the extent of clinical engagement — including medical history collection, contraindication screening, laboratory requirements, and follow-up protocols — across multiple platforms. The study characterized meaningful variation across vendors, with several platforms issuing prescriptions following minimal clinical interaction, limited or no review of comorbidities, and inadequate screening for known contraindications such as personal or family history of medullary thyroid carcinoma or pancreatitis risk factors.
This research arrives at a pivotal moment for GLP-1 pharmacology. These agents have demonstrated robust efficacy in large randomized trials — reducing body weight by 15–22% and conferring cardiovascular and renal benefits in high-risk populations — yet they carry a meaningful adverse-effect profile that demands individualized clinical assessment. The secret shopper methodology is a well-validated tool in health services research, lending credibility to the findings, though the study's scope is inherently limited to the platforms sampled and may not represent the full telehealth ecosystem. More importantly, the findings are observational and cannot quantify downstream patient harm. Nevertheless, this is not an incremental study — it provides the first systematic, empirical characterization of a prescribing channel now used by an estimated millions of Americans, and the gaps identified suggest that self-regulation by telehealth platforms is insufficient to protect vulnerable patients from inappropriate prescribing.